Submission Information

In all abstract categories, Basic/Pre-Clinical/Clinical abstracts are encouraged.

• Mesenchymal Stem/Stromal Cells
  • Basic science and preclinical studies
  • Manufacturing and regulatory
  • Clinical investigations
• Hematopoietic Stem/Progenitor Cells and Engineering
  • Basic science and preclinical studies
  • Manufacturing and regulatory
  • Clinical investigations
• Immunotherapy (CAR-T, T Reg, NK Cells etc.)
  • Basic science and preclinical studies
  • Manufacturing and regulatory
  • Clinical investigations
• Exosomes/EVs
  • Basic science and preclinical studies
  • Manufacturing and regulatory
  • Clinical investigations
• iPSC
  • Basic science and preclinical studies
  • Manufacturing and regulatory
  • Clinical investigations
• Gene Editing/Gene Therapies
  • Basic science and preclinical studies
  • Manufacturing and regulatory
  • Clinical investigations
• Tissue Engineering
  • Basic science and preclinical studies
  • Manufacturing and regulatory
  • Clinical investigations
• Embryonic, Organ and Other Tissue Specific Stem Cells
  • Basic science and preclinical studies
  • Manufacturing and regulatory
  • Clinical investigations
• Process Development & Manufacturing and Commercialization
  • Automation, Artificial Intelligence, machine learning
  • Technology transfer, intellectual property
  • Clinical development and validation (clinical trial design, patient population and selection)
  • Starting materials (auto vs allo, donor selection, apheresis, contamination)
  • Manufacturing facility design and operations
  • Supply chain logistics (material handling, international import/export)
  • Business Models (Cost of Goods, manufacturing operations model, scale up and out)
  • Partnering and investment strategies
• Regulatory Affairs, Quality Systems, Policy, Ethics, and Patient Access
  • Regulatory inspections, reporting & submissions (INDs, BLAs, compliance)
  • Regulatory convergence and harmonization
  • Accreditation (JACIE/FACT, GMP), Surveys and Registries
  • Legal aspects including consent and liability
  • Patient views / Patient advocacy
  • Policy development and implementation (non-trial access, patient access)
  • Market access (reimbursement)
  • Ethical issues in cell and gene therapy (direct-to-consumer clinics, medical tourism)
  • Quality Control (potency assays, proficiency testing, release testing)
  • Quality Assurance/Quality Management
• Workforce Development

• ISCT membership is not required to submit and present an abstract.
• The abstract body cannot exceed 2,500 characters, exclusive of the title, author block, images, and tables.
• Note that spaces count as characters.
• Ensure that any references to licensed products are labelled with their non-proprietary names.
• Abstracts must be submitted via the online Abstract Submission System. Abstracts will not be accepted by email, mail, or fax.
• There are limited opportunities for oral talks. Invitations to give an oral presentation are based on the quality and scope of the submitted abstract as determined through our blinded-review process.
• The inclusion of all relevant data to your topic is strongly encouraged as Reviewers will evaluate this when scoring submitted abstracts.
• ISCT may reject abstracts that are considered inappropriate for any reason. Abstracts, once submitted, can only be withdrawn no later than June 26, 2026. If not withdrawn by this deadline, all accepted abstracts will be published in the final program and abstract supplement.
• Abstract presenters must have full conference registration to present at the meeting.

• Abstracts submitted to the ISCT ANZ 2026 Regional Meeting is embargoed from the time of submission until 23:59 AEST July 10, 2026
• To be eligible for presentation, information within the abstract (and additional data to be presented) may not be published elsewhere or made public before the abstract has been published/presented at the ISCT ANZ 2026 Regional Meeting.
• Authors must notify ISCT if, after the submission deadline, the submitted abstract is accepted for publication elsewhere and will be published before the meeting. Publication before the meeting may result in the abstract being removed from the conference.
• If the Embargo Policy is violated, the abstract may be withdrawn by ISCT from presentation and from publication in the abstract supplement.

* An embargo means that information from any abstract or presentation may not be announced, publicized, or distributed before the embargo date and time.

• ISCT generally does not accept encore abstracts unless there are substantial data updates.
• Exceptions may be granted upon written request to elizabeth@isctglobal.org, with a clear justification for the encore abstract (e.g., if the ISCT audience significantly differs from the initial presentation).

* An encore abstract is the resubmission of an original abstract that has previously been presented at another conference.